...The Morphotek Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523) granted Fujirebio Inc. (Tokyo, Japan) exclusive, worldwide rights...
...assay as a companion diagnostic to identify ovarian cancer patients who may best respond to Morphotek's...
...with carboplatin plus taxane to treat relapsed, platinum-sensitive ovarian cancer in a Phase III trial. Morphotek...

...Eisai’s Morphotek Inc. subsidiary granted Eurofarma exclusive, Latin American rights to develop and commercialize farletuzumab, a humanized...
...first relapse in patients with low levels of mucin 16 ( MUC16 ; CA125 ). Morphotek...

...Eisai’s Morphotek Inc. subsidiary partnered with the Targeted Alpha Therapy (TAT) Group at the university to research...

...Eisai’s Morphotek Inc. subsidiary granted Blaze an exclusive, worldwide license to develop and commercialize a tumor-targeting chlorotoxin...
...activated epithelial cells. It has completed a Phase II trial in patients with recurrent glioma. Morphotek...
...the technology for its pipeline, said it will determine specific indications for the chlorotoxin derivative. Morphotek...

...Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II ARTEMIS trial to evaluate 5 mg/kg...

...Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II 003-011 trial to evaluate 5 mg/kg...

...Eisai’s Morphotek Inc. subsidiary and Sorrento’s Concortis Biosystems Inc. subsidiary partnered to generate antibody-drug conjugates (ADCs) based...
...antibody-drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutics using Concortis’ ADC technology. Morphotek...
...research fees and is eligible to receive up to $50 million in milestones, plus royalties. Morphotek...

...Eisai's Morphotek Inc. subsidiary said the Children's Oncology Group began an open-label, U.S. Phase I trial to...
...IV MORAb-004 once weekly in about 65 pediatric patients with recurrent or refractory solid tumors. Morphotek...

...in ovarian cancer based on discussion with external experts and health authorities. In 2011, Eisai's Morphotek Inc....

...strategy for farletuzumab based on discussion with external experts and health authorities. In 2011, Eisai's Morphotek Inc....